948581-72-4 Usage
Uses
Used in Pharmaceutical Industry:
7-Chloro-4-methoxy-1H-indole is used as a building block for the synthesis of various biologically active compounds, contributing to the development of new pharmaceuticals. Its unique structure and reactivity enable the creation of diverse drug candidates with potential therapeutic applications.
Used in Agrochemical Industry:
In addition to its pharmaceutical applications, 7-chloro-4-methoxy-1H-indole is also utilized as a key intermediate in the production of agrochemicals. Its chemical properties allow for the development of effective compounds for agricultural and pest control purposes.
Used in Drug Development:
7-Chloro-4-methoxy-1H-indole is employed in drug development for its potential pharmacological properties. It has been studied for its possible use in the treatment of various diseases and conditions, making it a promising candidate for further research and development in the medical field.
Check Digit Verification of cas no
The CAS Registry Mumber 948581-72-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,4,8,5,8 and 1 respectively; the second part has 2 digits, 7 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 948581-72:
(8*9)+(7*4)+(6*8)+(5*5)+(4*8)+(3*1)+(2*7)+(1*2)=224
224 % 10 = 4
So 948581-72-4 is a valid CAS Registry Number.
InChI:InChI=1/C9H8ClNO/c1-12-8-3-2-7(10)9-6(8)4-5-11-9/h2-5,11H,1H3
948581-72-4Relevant academic research and scientific papers
SUBSTITUTED 4-HYDROXY-N- (4-HYDROXYPHENYL) INDOLES AS ESTROGENIC AGENTS
-
Page/Page column 19, (2009/10/18)
The present invention relates to novel indole derivatives having pharmacological activity, processes for their preparation, compositions containing them and the use of these compounds in the treatment of estrogen receptor beta mediated diseases.
17 BETA HSD TYPE 5 INHIBITOR
-
Page/Page column 22, (2008/12/08)
To provide a novel and excellent method for treating and/or preventing prostatic cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, polycystic ovary syndrome, breast cancer, lung cancer, endometriosis, leiomyoma and the like based on selective inhibitory activity against 17βHSD type 5. It was found that an N-sulfonylindole derivative, where the indole ring is substituted by a carboxy group, a carboxy-substituted lower alkyl group or a carboxy-substituted lower alkenyl group at its carbon atom, has potent selective inhibitory activity against 17βHSD type 5 and may become a therapeutic agent and/or preventive agent for benign prostatic hyperplasia, prostatic cancer and the like without accompanying adverse drug reactions due to a decrease in testosterone; and the present invention has thus been completed.
